Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA to Regulate Telehealth Prescribing; Spravato Sales Top $1bn Post published:February 10, 2025 Post category:Analysis/News/Pα+
GH Research Reports Strong Phase 2b Results for 5-MeO-DMT in Treatment-Resistant Depression Post published:February 3, 2025 Post category:Analysis/News/Pα+
2025’s Psychedelic Policy Surge: A State-by-State, Bill-by-Bill Analysis Post published:January 31, 2025 Post category:Analysis/News/Pα+
Psychedelic Drug Development Pipeline Updates (Q1’25) Post published:January 30, 2025 Post category:2024 Year in Review/Analysis/News/Pα+
Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart Post published:January 30, 2025 Post category:2024 Year in Review/Analysis
Bifurcation Squared: Compass Lobbies for Narrow Rescheduling in Colorado, Virginia; Pushes Back on State Policy Reforms Post published:January 23, 2025 Post category:Analysis/News
Psychedelics in 2024: From Hype to Hard Realities Post published:January 21, 2025 Post category:2024 Year in Review/Analysis/News
PsychedeliCare Launches First European Citizens’ Initiative Demanding Political Action on Psychedelic-Assisted Therapies Post published:January 14, 2025 Post category:Analysis/News
Billionaire Investor Antonio Gracias Plots $100M Lykos Takeover with Doblin’s Backing Post published:January 10, 2025 Post category:Analysis/News/Pα+
From Fringe to Focus: APA’s American Journal of Psychiatry Publishes Special Issue on Psychedelics Post published:January 7, 2025 Post category:Analysis/News/Pα+